204 related articles for article (PubMed ID: 18334913)
1. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
[TBL] [Abstract][Full Text] [Related]
2. Interaction between Apolipoprotein E and Butyrylcholinesterase Genes on Risk of Alzheimer's Disease in a Prospective Cohort Study.
Chuang YF; Varma V; An Y; Tanaka T; Davatzikos C; Resnick SM; Thambisetty M
J Alzheimers Dis; 2020; 75(2):417-427. PubMed ID: 32250307
[TBL] [Abstract][Full Text] [Related]
3. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.
Ferris S; Nordberg A; Soininen H; Darreh-Shori T; Lane R
Pharmacogenet Genomics; 2009 Aug; 19(8):635-46. PubMed ID: 19617863
[TBL] [Abstract][Full Text] [Related]
4. Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment.
Pyun JM; Park YH; Lee KJ; Kim S; Saykin AJ; Nho K;
Transl Neurodegener; 2021 Aug; 10(1):32. PubMed ID: 34465370
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the gene dose-effects of the APOE ε4 and ε2 alleles on hippocampal volumes in aging and Alzheimer's disease.
Hostage CA; Roy Choudhury K; Doraiswamy PM; Petrella JR;
PLoS One; 2013; 8(2):e54483. PubMed ID: 23405083
[TBL] [Abstract][Full Text] [Related]
6. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.
Kennedy RE; Cutter GR; Schneider LS
Alzheimers Dement; 2014 May; 10(3):349-59. PubMed ID: 23712001
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E ε4 allele interacts with sex and cognitive status to influence all-cause and cause-specific mortality in U.S. older adults.
Beydoun MA; Beydoun HA; Kaufman JS; An Y; Resnick SM; O'Brien R; Ferrucci L; Zonderman AB
J Am Geriatr Soc; 2013 Apr; 61(4):525-34. PubMed ID: 23581910
[TBL] [Abstract][Full Text] [Related]
8. Predicting the apolipoprotein E ε4 allele carrier status based on gray matter volumes and cognitive function.
Kim HG; Tian Y; Jung SM; Park S; Rhee HY; Ryu CW; Jahng GH
Brain Behav; 2024 Jan; 14(1):e3381. PubMed ID: 38376028
[TBL] [Abstract][Full Text] [Related]
9. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.
Schuff N; Woerner N; Boreta L; Kornfield T; Shaw LM; Trojanowski JQ; Thompson PM; Jack CR; Weiner MW;
Brain; 2009 Apr; 132(Pt 4):1067-77. PubMed ID: 19251758
[TBL] [Abstract][Full Text] [Related]
10. Age, APOE and sex: Triad of risk of Alzheimer's disease.
Riedel BC; Thompson PM; Brinton RD
J Steroid Biochem Mol Biol; 2016 Jun; 160():134-47. PubMed ID: 26969397
[TBL] [Abstract][Full Text] [Related]
11. Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort.
Teng E; Chow N; Hwang KS; Thompson PM; Gylys KH; Cole GM; Jack CR; Shaw LM; Trojanowski JQ; Soares HD; Weiner MW; Apostolova LG;
Dement Geriatr Cogn Disord; 2015; 39(3-4):154-66. PubMed ID: 25547651
[TBL] [Abstract][Full Text] [Related]
12. Racial differences in the effect of APOE-ε4 genotypes on trail making test B in Alzheimer's disease: A longitudinal study.
Xu C; Acevedo P; Lu Y; Su BB; Ozuna K; Padilla V; Karithara A; Mao C; Navia RO; Piamjariyakul U; Wang K;
Int J Geriatr Psychiatry; 2023 Dec; 38(12):e6037. PubMed ID: 38100638
[TBL] [Abstract][Full Text] [Related]
13. APOE ε4, Alzheimer's disease pathology, cerebrovascular disease, and cognitive change over the years prior to death.
Yu L; Boyle P; Schneider JA; Segawa E; Wilson RS; Leurgans S; Bennett DA
Psychol Aging; 2013 Dec; 28(4):1015-23. PubMed ID: 23647000
[TBL] [Abstract][Full Text] [Related]
14. Independent and combined effects of methamphetamine use disorders and APOEε4 allele on cognitive performance and brain morphometry.
Wang HA; Liang HJ; Ernst TM; Nakama H; Cunningham E; Chang L
Addiction; 2023 Dec; 118(12):2384-2396. PubMed ID: 37563863
[TBL] [Abstract][Full Text] [Related]
15. APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study.
Suchy-Dicey A; Howard B; Longstreth WT; Reiman EM; Buchwald D
Alzheimers Dement; 2022 Dec; 18(12):2518-2526. PubMed ID: 35142437
[TBL] [Abstract][Full Text] [Related]
16. Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program.
Walsh T; Duff L; Riviere ME; Tariot PN; Doak K; Smith M; Borowsky B; Lopez Lopez C; Arratia PC; Liu F; Scholten I; Gordon D; Arbuckle J; Graf A; Quinn M; Ricart J; Langbaum JB
J Prev Alzheimers Dis; 2023; 10(3):453-463. PubMed ID: 37357285
[TBL] [Abstract][Full Text] [Related]
17. Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease.
Qian W; Fischer CE; Schweizer TA; Munoz DG
Curr Alzheimer Res; 2018; 15(2):187-194. PubMed ID: 28847281
[TBL] [Abstract][Full Text] [Related]
18. Gene-behavior interaction of depressive symptoms and the apolipoprotein E {varepsilon}4 allele on cognitive decline.
Rajan KB; Wilson RS; Skarupski KA; Mendes de Leon CF; Evans DA
Psychosom Med; 2014 Feb; 76(2):101-8. PubMed ID: 24434953
[TBL] [Abstract][Full Text] [Related]
19. Interaction between
Chen XR; Shao Y; Sadowski MJ; On Behalf Of The Alzheimer's Disease Neuroimaging Initiative
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107675
[No Abstract] [Full Text] [Related]
20. APOE ε4 genotype predicts memory for everyday activities.
Bailey HR; Sargent JQ; Flores S; Nowotny P; Goate A; Zacks JM
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2015; 22(6):639-66. PubMed ID: 25754878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
